MedTrace Logo

Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis

NCT00385645 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 255

Last updated 2010-03-31

No results posted yet for this study

Summary

The study compares the adherence of 240 HIV-negative subjects randomly assigned to 2 different antiretroviral therapies for 28 days after accidental exposure to HIV.

Conditions

  • HIV Infections

Interventions

DRUG

Combivir+Kaletra

DRUG

Combivir+Reyataz

Sponsors & Collaborators

  • Hospital Clinic of Barcelona

    lead OTHER

Principal Investigators

  • Felipe Garcia, MD · Hospital Clinic of Barcelona

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00385645 on ClinicalTrials.gov